scholarly journals МЕТАБОЛІТОТРОПНА ТЕРАПІЯ В ЛІКУВАННІ ПАЦІЄНТІВ ІЗ ГІПЕРТОНІЧНОЮ ХВОРОБОЮ ІІ СТАДІЇ У ПОЄДНАННІ З СТАБІЛЬНОЮ ІШЕМІЧНОЮ ХВОРОБОЮ СЕРЦЯ

2018 ◽  
Author(s):  
V. V. Boyko ◽  
S. V. Biletskyi
Keyword(s):  
Nitrogen Monoxide ◽  
Immunoreactive Insulin ◽  
No Donor ◽  
Vascular Growth ◽  
Vascular Growth Factor ◽  
Arginine Hydrochloride ◽  
Increased Activity ◽  
Reliable Increase ◽  
Baseline Therapy ◽  
Γ2 Gene

In the treatment of arterial hypertension (AH), stable ischemic heart disease (SIHD), correction of metabolic factors of cardiovascular risk using antioxidants and nitrogen monoxide (NO) donor agents is extremely important.The aim of the study – to investigate the effectiveness of treatment of patients with AH of the II stage in conjunction with SIHD by influencing with Quercetin (Corvitin) and Arginine hydrochloride (Tivortin) upon the lipid and carbohydrate metabolism indices, the intensity of peroxide lipid oxidation (LPO), and the endothelial function.Materials and Methods. The study involved 56 patients with AH of the II stage concomitant with SIHD, which were randomized into two groups. The 1st group consisted of 24 patients, who received a common baseline therapy (BT). Patients of the 2nd group (32 persons) received infusion Corvitin therapy (0.5 g) besides BT during the first 6 days, and 100 ml of intravenous Tivortin solution during the next 6 days, followed by the outpatient oral administration of 10 ml of Tivortin 2 times per day during two weeks.Results and Discussion. The use of Corvitin and Tivortin against the background of BT in patients with AH of the II stage in combination with SIHD has led to a significant improvement of lipidogram indices, decreased plasma glucose concentration, immunoreactive insulin (IRI), HOMA -IR index, plasma malonic aldehyde (MA) and erythrocytes. Reliable increase in the content of reduced glutathione (RG), increased activity of glutathione peroxidase (GP), catalase (CT) has been marked from the side of antioxidant protection (AOP). There was a significant increase in the content of end-metabolites of NO by 22.2 %, of the endothelial vascular growth factor VEG F-A – by 38.2 %. A more significant indices dynamics is observed in patients with the genotype Pro/Ala of the PPAR γ2 gene.

scholarly journals XPS Modeling of Immobilized Recombinant Angiogenin and Apoliprotein A1 on Biodegradable Nanofibers

Nanomaterials ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 879
Author(s):  
Anton Manakhov ◽  
Elizaveta Permyakova ◽  
Sergey Ershov ◽  
Svetlana Miroshnichenko ◽  
Mariya Pykhtina ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Growth Factor ◽  
Photoelectron Spectroscopy ◽  
Antioxidant Activities ◽  
Fluorescent Microscopy ◽  
X Ray ◽  
Vascular Growth ◽  
Vascular Growth Factor ◽  
And Migration ◽  
Protein Density

The immobilization of viable proteins is an important step in engineering efficient scaffolds for regenerative medicine. For example, angiogenin, a vascular growth factor, can be considered a neurotrophic factor, influencing the neurogenesis, viability, and migration of neurons. Angiogenin shows an exceptional combination of angiogenic, neurotrophic, neuroprotective, antibacterial, and antioxidant activities. Therefore, this protein is a promising molecule that can be immobilized on carriers used for tissue engineering, particularly for diseases that are complicated by neurotrophic and vascular disorders. Another highly important and viable protein is apoliprotein A1. Nevertheless, the immobilization of these proteins onto promising biodegradable nanofibers has not been tested before. In this work, we carefully studied the immobilization of human recombinant angiogenin and apoliprotein A1 onto plasma-coated nanofibers. We developed a new methodology for the quantification of the protein density of these proteins using X-ray photoelectron spectroscopy (XPS) and modeled the XPS data for angiogenin and apoliprotein A1 (Apo-A1). These findings were also confirmed by the analysis of immobilized Apo-A1 using fluorescent microscopy. The presented methodology was validated by the analysis of fibronectin on the surface of plasma-coated poly(ε-caprolactone) (PCL) nanofibers. This methodology can be expanded for other proteins and it should help to quantify the density of proteins on surfaces using routine XPS data treatment.

scholarly journals Paracrine potential of fibroblasts exposed to cigarette smoke extract with vascular growth factor induction

2013 ◽  
Vol 123 (9) ◽  
pp. 2228-2236 ◽  
Author(s):  
Craig M. Berchtold ◽  
Adam Coughlin ◽  
Zachary Kasper ◽  
Susan L. Thibeault
Keyword(s):  
Growth Factor ◽  
Cigarette Smoke ◽  
Cigarette Smoke Extract ◽  
Vascular Growth ◽  
Vascular Growth Factor

scholarly journals Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti–Vascular Growth Factor Agents in a Nationwide Study in France

2018 ◽  
Vol 136 (12) ◽  
pp. 1352 ◽  
Author(s):  
Florian Baudin ◽  
Eric Benzenine ◽  
Anne-Sophie Mariet ◽  
Alain M. Bron ◽  
Vincent Daien ◽  
...  
Keyword(s):  
Growth Factor ◽  
Intravitreal Injections ◽  
Nationwide Study ◽  
Vascular Growth ◽  
Vascular Growth Factor

scholarly journals Myopericytoma arising from myopericytosis—a hitherto unrecognized entity within the lung

2020 ◽  
Author(s):  
Ulrike Gruber-Moesenbacher ◽  
Alicia Morresi- Hauff ◽  
Katja Behr ◽  
Helmut Popper
Keyword(s):  
Differential Diagnosis ◽  
Growth Factor ◽  
Kinase Inhibitors ◽  
Antiangiogenic Therapy ◽  
Angiogenesis Inhibitor ◽  
Precursor Lesion ◽  
Specific Therapy ◽  
Vascular Growth ◽  
Vascular Growth Factor ◽  
Pulmonary Tumors

AbstractTwo cases of myopericytosis combined with pericytoma originating within the lung are reported. These are rare pulmonary tumors. The differential diagnosis for hemangiopericytoma and pericytic tumors with glomus elements is discussed. Both myopericytic lesions mimic other lesions, which are more commonly seen in the lung. Based on the expression of vascular growth factor receptors 2 and 3, an antiangiogenic therapy was suggested for the patient with the myopericytoma. A treatment with an angiogenesis inhibitor resulted in a regression of the tumor, but not the precursor lesion. Probably a more specific therapy using tyrosine kinase inhibitors for VEGFR2/3 might better control these myopericytic proliferations.

Angiogenesis and Vascular Growth Factor Receptor Expression in Malignant Melanoma

1999 ◽  
Vol 104 (6) ◽  
pp. 1666-1674 ◽  
Author(s):  
Eric Y. Lin ◽  
Michael Piepkorn ◽  
Rochelle Garcia ◽  
David Byrd ◽  
Raymond Tsou ◽  
...  
Keyword(s):  
Growth Factor ◽  
Malignant Melanoma ◽  
Growth Factor Receptor ◽  
Receptor Expression ◽  
Vascular Growth ◽  
Vascular Growth Factor

P.087 Salivary vascular growth factor in oral cancer prognosis

2008 ◽  
Vol 36 ◽  
pp. S190
Author(s):  
M. Vourvachis ◽  
T. Upile ◽  
W. Jerjes ◽  
S. Singh ◽  
C. Hopper
Keyword(s):  
Growth Factor ◽  
Oral Cancer ◽  
Cancer Prognosis ◽  
Vascular Growth ◽  
Vascular Growth Factor

Vascular Growth Factors in Patients with Sickle Cell Disease.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3787-3787
Author(s):  
Ashley J. Duits ◽  
John B. Schnog
Keyword(s):  
Growth Factor ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Serum Levels ◽  
Cell Disease ◽  
Vascular Growth ◽  
Vascular Growth Factor ◽  
Vessel Maturation ◽  
History Of ◽  
Angiopoietin 2

Abstract Angiogenesis plays a central role in neovascular processes. In sickle cell patients neovascularization is considered a common feature that is associated with complications such as retinopathy and cerebrovascular disease. Several studies have reported increased vascular growth factor levels such as vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) in small groups of patients. Recently the angiopoietin/Tie2 system has been shown to be of major importance in vessel maturation. In order to thoroughly characterize vascular growth factor profiles in sickle cell patients we analyzed serum levels of VEGF, PlGF, Angiopoietin-1, Angiopoietin-2, Tie-2 and erythropoietin (EPO) during the asymptomatic phase as well as during painful crises in HbSS patients (n=42) and compared these to levels in HbAA controls (n=30). Also, levels were compared between patients with and without a history of acute vaso-occlusive complications the year prior to sample collection. Serum Angiopoietin-2, Tie-2 and EPO levels were significantly higher in sickle cell patients as compared to controls (p<0.01, p=0.03 and p<0.01 respectively), whereas PlGF and VEGF serum levels were similar between patients and controls (p= 0.21 and p=0.5). Only Angiopoietin-2 and EPO serum levels were significantly increased in sickle cell patients during acute vaso-occlusive crises as compared to levels in asymptomatic patients (p<0.01 and p=0.03 respectively). No differences were detected in measured parameters between patients with a history of acute vaso-occlusive complications as compared to patients without acute vaso-occlusive complications in the preceding year. Our results show a specific pattern of angiopoietins in sickle cell patients. Considering the importance of endothelial cell activation in sickle cell disease and the regulation of endothelial cell survival and blood vessel maturation by the angiopoietin/Tie-2 system, further analysis of angiogenesis in sickle cell disease is warranted.

Sign in / Sign up

Export Citation Format

Share Document